MAZEMaze Therapeutics, Inc.

$29.59

Who owns MAZE

164 institutions reported holding MAZE for 2026Q1, together 96% of the company, more than the 142 a quarter earlier.

164

Institutions reporting a position · as of 2026Q1 · up from 142 the quarter before

Shares held by institutions
51.7M

Shares held by institutions · 96% of the company · long US equity positions only, as reported on Form 13F

Reported value
$1.54B

Reported value · at 2026-03-31 prices, not today's

Top 5 holders
36%

Top 5 holders · of the whole company, between five filers

Details
Reporting quarter2026-03-31
2026Q1
Quarters on record
5
New positions
44
Positions exited
26
Added to
57
Reduced
36
Top 10 holdersof the company
56%
Institutional ownership by quarter, 2025Q1 to 2026Q1
QuarterFilersSharesReported value
2026Q116451.7M$1.54B
2025Q414248.4M$2.00B
2025Q39343.0M$1.11B
2025Q27538.8M$477M
2025Q16840.0M$441M
Largest reported holders, 2026Q1
HolderShares% of companyValue
Frazier Life Sciences Management, L.P.4.6M8.5%$136M
TRV GP IV, LLC4.5M8.3%$134M
ARCH Venture Management, LLC4.1M7.6%$123M
Deep Track Capital, LP3.5M6.5%$104M
HENDERSON GROUP PLC2.9M5.3%$85M
Paradigm Biocapital Advisors LP2.7M5.1%$82M
BlackRock Inc.2.6M4.8%$77M
VANGUARD GROUP INC1.8M3.3%$54M
a16z Capital Management, L.L.C.1.7M3.2%$51M
Venrock Adviser, LLC1.6M3.0%$48M

SEC Form 13F data sets (DERA bulk files). 13F is quarterly, filed up to 45 days late, and covers long US equity positions only, no shorts, no derivatives, nothing held below the reporting threshold.

reading the register…